On the fringes of the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam in April 2016, four eminent players in the fight against antimicrobial resistance (AMR) came around the table with Scrip to discuss the current state of play and where the most pressing needs lie.
Joining moderator Eleanor Malone, editor of Scrip, were
This is an edited version of the round table, which was sponsored by AstraZeneca. Scrip will publish the full audio...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
